Literature DB >> 26830627

15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.

Preeti Vishwakarma1,2, Naveen Parmar1,2, Pawan Kumar Yadav1,2, Pragya Chandrakar1,2, Susanta Kar3,4.   

Abstract

UNLABELLED: 15-Deoxy-delta (12,14)-prostaglandin J2 (15d-PgJ2) is a potent bioactive lipid mediator, known to possess several roles in cell regulation and differentiation along with antimicrobial efficacy against different bacterial and viral infections. In the present study, we investigated the therapeutic efficacy and mechanism of action of 15d-PgJ2 in vitro in Leishmania donovani promastigotes and infected J774 macrophages, and in vivo in Balb/c mice/golden hamster model of experimental visceral leishmaniasis. 15d-PgJ2 effectively killed L. donovani promastigotes and amastigotes in vitro with IC50 of 104.6 and 80.09 nM, respectively. At 2 mg/kg (mice) and 4 mg/kg (hamster) doses, 15d-PgJ2 decreased >90 % spleen and liver parasite burden. It significantly reduced interleukin (IL)-10 and transforming growth factor (TGF)-β synthesis in infected macrophages and splenocytes. 15d-PgJ2 induced reactive oxygen species (ROS)-dependent apoptosis of promastigotes by triggering phosphatidyl serine externalization, mitochondrial membrane damage and inducing caspase-like activity. In vitro drug interaction studies revealed an indifference to the synergistic association of 15d-PgJ2 with Miltefosine and Amphotericin-B (Amp-B). Moreover, when combined with sub-curative doses of Miltefosine and Amphotericin-B, 15d-PgJ2 resulted in >95 % parasite removal. Our results suggested that 15d-PgJ2 induces mitochondria-dependent apoptosis of L. donovani and is a good therapeutic candidate for adjunct therapy against experimental visceral leishmaniasis. KEY MESSAGE: 15d-PgJ2 effectively eliminated both promastigotes and amastigotes form of L. donovani. 15d-PgJ2 decreased parasite burden from infected mice and hamsters with reduced Th2 cytokines. 15d-PgJ2 induced ROS-mediated mitochondrial apoptosis of L. donovani promastigotes. 15d-PgJ2 is a good therapeutic candidate for adjunct therapy with Miltefosine and Amp-B.

Entities:  

Keywords:  15d-Prostaglandin J2; Apoptosis; Combination therapy; IL-10; L. donovani; ROS

Mesh:

Substances:

Year:  2016        PMID: 26830627     DOI: 10.1007/s00109-016-1384-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  54 in total

1.  The first total synthesis of 15-deoxy-Delta12,14-prostaglandin J2 and the unambiguous assignment of the C14 stereochemistry.

Authors:  Kay M Brummond; Peter C Sill; Hongfeng Chen
Journal:  Org Lett       Date:  2004-01-22       Impact factor: 6.005

2.  Prostaglandin-induced programmed cell death in Trypanosoma brucei involves oxidative stress.

Authors:  K Figarella; N L Uzcategui; A Beck; C Schoenfeld; B K Kubata; F Lang; M Duszenko
Journal:  Cell Death Differ       Date:  2006-02-03       Impact factor: 15.828

3.  Prostaglandins antagonistically control Bax activation during apoptosis.

Authors:  L Lalier; P-F Cartron; C Olivier; C Logé; G Bougras; J-M Robert; L Oliver; F M Vallette
Journal:  Cell Death Differ       Date:  2010-10-22       Impact factor: 15.828

4.  Delta(12)-prostaglandin J(2) is a potent inhibitor of influenza A virus replication.

Authors:  F Pica; A T Palamara; A Rossi; A De Marco; C Amici; M G Santoro
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 5.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

Review 6.  Prostaglandin D2 and sleep regulation.

Authors:  Y Urade; O Hayaishi
Journal:  Biochim Biophys Acta       Date:  1999-01-04

7.  15-Deoxy-Delta12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification.

Authors:  Parisa Kalantari; Vivek Narayan; Andrew J Henderson; K Sandeep Prabhu
Journal:  FASEB J       Date:  2009-03-19       Impact factor: 5.191

8.  15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.

Authors:  Sung-Won Shin; Chi-Yeon Seo; Hoon Han; Jin-Yeong Han; Jin-Sook Jeong; Jong-Young Kwak; Joo-In Park
Journal:  Clin Cancer Res       Date:  2009-08-18       Impact factor: 12.531

9.  Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.

Authors:  B Resul; J Stjernschantz; K No; C Liljebris; G Selén; M Astin; M Karlsson; L Z Bito
Journal:  J Med Chem       Date:  1993-01-22       Impact factor: 7.446

Review 10.  Visceral leishmaniasis: experimental models for drug discovery.

Authors:  Suman Gupta
Journal:  Indian J Med Res       Date:  2011-01       Impact factor: 2.375

View more
  5 in total

Review 1.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

Review 2.  Crosstalk between purinergic receptors and lipid mediators in leishmaniasis.

Authors:  Mariana M Chaves; Cláudio Canetti; Robson Coutinho-Silva
Journal:  Parasit Vectors       Date:  2016-09-05       Impact factor: 3.876

3.  Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B.

Authors:  Md Shadab; Baijayanti Jha; Mohammad Asad; Makaraju Deepthi; Mohd Kamran; Nahid Ali
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

4.  Lipid droplets of protozoan parasites: survival and pathogenicity.

Authors:  Victor de Souza Tavares; Monara Viera de Castro; Rayane da Silva Oliveira Souza; Iana Kátia Araújo Gonçalves; Jonilson Berlink Lima; Valéria de Matos Borges; Théo Araújo-Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-02-16       Impact factor: 2.743

Review 5.  Inflammatory and Pro-resolving Lipids in Trypanosomatid Infections: A Key to Understanding Parasite Control.

Authors:  Rodrigo A López-Muñoz; Alfredo Molina-Berríos; Carolina Campos-Estrada; Patricio Abarca-Sanhueza; Luis Urrutia-Llancaqueo; Miguel Peña-Espinoza; Juan D Maya
Journal:  Front Microbiol       Date:  2018-08-21       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.